Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sound waves aim to tame Huntington's tremors

NCT ID NCT07513844

Symptom relief Sponsor: First Affiliated Hospital of Fujian Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether low-intensity focused ultrasound (LIFU) can safely improve motor symptoms in 24 adults with Huntington's disease. Participants receive ultrasound pulses to a brain region involved in movement control. The study focuses on safety and finding the best pulse frequency, while also measuring changes in movement scores.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Low-intensity focused ultrasound (LIFU) device
What this could lead to
If successful, this could point toward a non-invasive way to ease movement problems in Huntington's disease.
What could go wrong
This is a very early, small safety trial (24 people). It may not show clear benefit, and risks include seizures, mood changes, or brain swelling.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 18 to 75 years (inclusive) 2. Genetically confirmed Huntington's disease with HTT CAG repeat length of 40 or greater 3. Unified Huntington's Disease Rating Scale Total Maximal Chorea score of 8 or higher on a scale of 0 to 28, with higher scores indicating more severe chorea 4. Huntington's Disease Integrated Staging System stage 2 or 3 5. Willing to participate and provide informed consent 6. Have a reliable caregiver available 7. No severe cognitive impairment that would preclude reliable reporting of adverse events or efficacy during treatment Exclusion Criteria: 1. History of self-injury, aggressive behavior, or unstable psychiatric disorders 2. History of head injury or neurosurgical procedure 3. Presence of intracranial implants, metallic foreign bodies, cochlear implants, or cardiac pacemakers 4. Severe systemic disease, pregnancy, or breastfeeding 5. Contraindications to magnetic resonance imaging, ultrasound, or anesthesia 6. Prior treatment with electroconvulsive therapy, transcranial magnetic stimulation, transcranial direct current stimulation, transcranial alternating current stimulation, or other neuromodulation therapies within the past 3 years 7. Severe brain atrophy with unclear external globus pallidus structure on MRI 8. Concurrent participation in another interventional clinical trial 9. Any other condition that, in the opinion of the investigator, would preclude participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Huntington disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Huntington disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Huntington disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Rehabilitation Medicine, The First Affiliated Hospital of Fujian Medical University

    RECRUITING

    Fuzhou, Fujian, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.